These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33340887)

  • 1. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer.
    Kim SJ; Sota Y; Naoi Y; Honma K; Kagara N; Miyake T; Shimoda M; Tanei T; Seno S; Matsuda H; Noguchi S; Shimazu K
    Transl Oncol; 2021 Feb; 14(2):100986. PubMed ID: 33340887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
    Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
    JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
    BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
    Chen J; Zhu Y; Wu W; Xu Y; Yang W; Ling L; Lin Q; Jia S; Xia Y; Liu Z; Yang Y; Gong C
    Oncologist; 2024 Jul; 29(7):e864-e876. PubMed ID: 38366907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.
    Feng C; Zhang Y; Wu F; Li J; Liu M; Lv W; Li C; Wang W; Tan Q; Xue X; Ma X; Zhang S
    Breast; 2023 Jun; 69():392-400. PubMed ID: 37116400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).
    Menzel M; Endris V; Schwab C; Kluck K; Neumann O; Beck S; Ball M; Schaaf C; Fröhling S; Lichtner P; Schirmacher P; Kazdal D; Stenzinger A; Budczies J
    Transl Oncol; 2023 Sep; 35():101706. PubMed ID: 37327584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
    Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination Abnormalities Associated With
    Albitar M; Zhang H; Pecora A; Waintraub S; Graham D; Hellmann M; McNamara D; Charifa A; De Dios I; Ma W; Goy A
    Breast Cancer (Auckl); 2023; 17():11782234231198979. PubMed ID: 37789896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    Zhang L; Chen Y; Cheng MY; Zhuang X; Zou J; Wei D; Lin YY; Zhang Y; Wang K
    Ther Adv Med Oncol; 2022; 14():17588359221096253. PubMed ID: 35547093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
    Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.